JIA is the most common chronic MSK condition in children and the most common cause of MSK disability.
Now Jordy himself is launching a support group called Arthritis Kids Unite to raise awareness of
JIA and raise money for Arthritis Research UK.
The new GT has been made possible thanks to an agreement between
JIA and Jensen Motor Group, which now owns the Jensen name.
JIA outcome measures have been validated and are now widely used in clinical trials, including the ACR Pedi 30/50/70.
The
JIA group was comprised of children diagnosed with
JIA at the Capital Institute of Pediatrics between February 2009 and December 2009.
JIA is a form of inflammatory joint disease that affects around 15,000 children in the UK.
Eighty-two of the patients had
JIA and 35 patients had FMF.
In contrast to a typical RA patient with other co-existing disease, children with
JIA have less co-morbidity, and may, therefore, better tolerate medications.
While there are a number of effective therapies available for
JIA, interviewed thought leaders are calling for the implementation of approaches that would improve treatment efficacy, including increased emphasis on patient-reported outcomes and availability of biomarkers to guide personalized therapy.
The drugs used in the treatment of
JIA are identical to those used in adult rheumatic diseases.
JIA is a general term used to describe the various chronic arthritis diseases in children.
As with most classification criteria in rheumatology, the diagnosis of
JIA is one of exclusion, obligating the clinician to rule out rheumatic, infectious, and other potential causes of chronic synovitis.
